A New York hospital executive walks into a congressional hearing and basically says, “Don’t blame me—blame everything.” That line, in my opinion, is more than a defense. It’s a window into how the U.S. health-care cost crisis is increasingly framed as an endless tug-of-war among variables: labor, drugs, supplies, incentives, subsidies, competition rules, federal cuts, market dynamics. And while each of those factors may be real, the way they’re used can also become a convenient fog machine—one that keeps the public from seeing where power actually sits.
What makes this particularly fascinating is how the argument turns on a philosophical question: are rising prices mostly the result of bad inputs and unavoidable economic pressure, or are they the result of market leverage and institutional strategy? Personally, I think the truth is messier than either side wants to admit, but the hearing shows a familiar pattern—policy debates become battles of attribution rather than blueprints for change.
Prices, as a shifting blame game
The CEO of NewYork-Presbyterian argued that price growth doesn’t come primarily from consolidation, but from climbing costs—labor, drugs, and medical supplies among other pressures. Factual? Likely yes, at least in part. But here’s what I think matters: pointing to general cost inflation is often a way to avoid confronting the question most people actually have, which is why the U.S. pays more than comparable health systems in other wealthy countries.
From my perspective, “basically everything” is not a policy position—it’s a diagnostic dead end. It tells lawmakers where to look for explanations, but it doesn’t tell them what to change, and that’s where accountability should live. What many people don’t realize is that health-care markets can keep prices high even when input costs rise, because pricing power, bargaining structures, and contract design can amplify those inputs rather than simply pass them through.
This raises a deeper question: when executives say the problem is universal, are they implicitly asking for universal relief—more funding, more flexibility, less scrutiny? In my opinion, that’s the subtext behind many cost arguments in health care, and the subtext is what determines outcomes.
Consolidation: a real concern, but not the whole story
Republicans at the hearing pressed the consolidation narrative, arguing that megacorporations put earnings ahead of quality. I’m not ideologically opposed to that concern—market concentration can absolutely affect bargaining leverage, especially when patients and providers have limited alternatives. But if you take a step back and think about it, consolidation is also a blunt instrument. Not every merger produces the same pricing behavior, and not every competitive market behaves the same way.
One detail that I find especially interesting is how the CEO tried to reframe New York City as unusually competitive, citing that several major systems operate there. Personally, I think that argument sounds plausible at first, yet it can miss what competition means in health care. “Competition” can exist on a map while still allowing dominant players to win contracts through network design, insurance relationships, and clinical referral patterns.
What this really suggests is that policymakers need to distinguish between the existence of multiple providers and the existence of meaningful switching by payers. If insurers believe excluding a system would be too risky or politically unpopular, then the system’s market share becomes a kind of gravity—even if other hospitals are nearby.
The DOJ lawsuit: contracting as the battleground
The hearing came shortly after the Department of Justice sued NewYork-Presbyterian over alleged insurance contract practices that suppress competition. The allegation—described in the source material—centers on network requirements that can effectively force insurers to include all facilities or none. Donley declined to comment on the charges, and the hospital’s spokesperson called the lawsuit without merit.
In my opinion, this is where the debate becomes less abstract. Cost increases are one thing; contract leverage is another. When pricing is shaped by how insurers must structure networks, you can have a market where formal competitors exist but practical access is controlled.
People often misunderstand this dynamic because they imagine competition as shoppers switching between brands. In health care, “switching” is constrained by referral pathways, clinical networks, patient loyalty, physician affiliations, and payer risk tolerance. That means contracting practices can change outcomes without anyone ever shouting “monopoly.”
This raises a broader perspective: even if input costs drive baseline expenses upward, contract power can decide who captures the margin. And margins, not hospital budgets, are what public debate should relentlessly focus on.
Telehealth and clinics: helpful, but do they move the needle?
The CEO pointed to cost-reduction efforts like shifting toward telehealth and investing in school health clinics and preventive programs. Personally, I think preventive care is morally compelling and often clinically sensible, but I’m skeptical about how quickly it can bend the cost curve in a system built on high-revenue volume.
Here’s my reasoning: prevention helps when it reduces downstream utilization, yet reimbursement structures and patient behavior often lag behind new strategies. Also, telehealth can expand access, but it can still be reimbursed in ways that don’t automatically compress spending—sometimes it just routes care differently, potentially increasing total throughput.
What makes this particularly important is that policymakers and the public sometimes assume “more prevention” is automatically “less cost.” In reality, prevention can improve outcomes while still coexisting with higher prices if the pricing engine remains intact. The question isn’t whether these initiatives are good; it’s whether they change bargaining leverage, unit prices, and contractual incentives.
The rural designation question: incentives and optics
Another line of questioning focused on NewYork-Presbyterian’s rural hospital designation and eligibility for federal subsidies. Rep. Richard Neal reportedly used an “East 68th Street” contrast to highlight the optics of rural status for an urban campus. Donley responded that the designation is allowed due to referrals from rural hospitals, with those patients comprising a subset of the system’s volume.
Personally, I think this exchange matters less as a gotcha and more as a case study in incentive design. Programs meant to support rural access can become complicated when systems with strong urban infrastructure serve as hubs for patients referred from farther away. That complexity isn’t inherently wrong—networks are real—but the public often experiences it as hypocrisy.
One thing that many people don’t realize is that administrative eligibility rules can be gamed by sophisticated organizations, even when the organization believes it is acting “within the rules.” Whether that leads to fairness or distortion depends on how the rule was drafted, audited, and enforced.
This suggests a deeper policy challenge: subsidy programs need transparency and accountability metrics that match their intended purpose, not just their eligibility labels.
“Coverage matters” amid political fights
Democrats on the committee, according to the source, shifted attention toward motives, suggesting Republicans used the hearing to distract from federal health-care cuts pursued last year. Policy analysts cited in the source material warn that those cuts could reduce insurance coverage and cut funding for hospitals. Meanwhile, the hospital system cited anticipated loss of federal funding and referenced disputes such as nurses’ salary demands.
From my perspective, this is the part of the story that’s easy to overlook when everyone is focused on consolidation and contracting. A health-care system that relies on stable coverage levels behaves differently than one exposed to sudden coverage reductions. If fewer people are insured, hospitals can face revenue volatility, which can influence pricing strategies even when the system claims to prioritize affordability.
What this really implies is that cost debates can’t be separated from insurance policy. If the public wants stable pricing, lawmakers also have to ensure there’s stable demand funded through coverage, or else the financial pressures will reappear as higher charges and budget shortfalls.
Medicare for All: support without specificity
When asked about a Medicare for All model, Donley reportedly supported insurance coverage for all but did not provide specific policy recommendations about what that should look like. Personally, I think this is a strategically vague position that reveals a core tension in industry responses to single-payer proposals: leaders often like the goal (universal coverage) while fearing the operational details (rate setting, payment redesign, market disruption).
What makes this particularly fascinating is how “coverage for all” is sometimes treated as a value statement rather than a structural transformation. In my opinion, the operational design determines whether universal coverage becomes a tool for price discipline or simply another payer for an unchanged pricing system.
This leads to a practical question most people don’t ask in hearings: if you change who pays but not how prices form, do you actually reduce spending? Or do you just reorganize the flow of money while leaving the bargaining engine mostly intact?
So what is driving costs—inputs or leverage?
If I combine the hearing’s competing frames, a picture emerges: rising health-care costs are influenced by input inflation and administrative burden, but they are also influenced by how organizations negotiate payment, structure networks, and use market power. Personally, I think the most misleading debate is the one that insists it’s only one or the other. The system is built to translate multiple pressures into higher charges.
That’s why the “blame basically everything” stance can be partially truthful yet politically evasive. It can correctly acknowledge labor and drug pressures while dodging the question of whether pricing is being aggressively protected through contracting, network constraints, and subsidy optimization.
The broader trend I see—across policy circles—is that hearings increasingly become contests of narrative. Each side tries to control what counts as the “real” cause, because whoever defines causality tends to define solutions. In my view, the public should demand causality with evidence, not just causality with plausible-sounding categories.
What we should demand next
If lawmakers want to reduce prices, they should push beyond generic blame and toward measurable constraints on pricing power and contract leverage. Personally, I think that means focusing on the mechanisms that govern unit prices and network access, not just tallying cost pressures.
Here are a few directions that follow logically from what was argued in the hearing and the DOJ action:
- Tighten scrutiny of network contracting practices, especially arrangements that limit insurer flexibility.
- Evaluate payment differentials more rigorously to determine whether they reflect true added value or mere bargaining leverage.
- Make subsidy eligibility and referral-based claims more transparent, with auditing that matches the purpose of the program.
- Link coverage stability reforms to hospital payment reforms, because coverage shocks can indirectly worsen pricing dynamics.
I’m not saying these are easy fixes. I am saying they are the kind of structural moves that match what the public intuitively senses: the health-care system doesn’t just cost more—it charges more.
Final takeaway
The CEO’s argument—costs are rising because labor, drugs, supplies, and pressures are rising—sounds reasonable, and it might even be partially correct. But personally, I think the hearing exposed something deeper: in health care, “rising costs” often functions as a cover story for “rising capture,” meaning the portion of value controlled through market leverage.
If you take this moment seriously, the real question isn’t whether inputs rose. It’s whether the system’s power structures turned those inputs into profit and pricing insulation. And that’s the uncomfortable debate Congress should keep forcing—because that’s where real reform usually starts.
